HY6-F9DF215

HY6-F9DF215 is a monoclonal antibody investigated for the treatment of synthetic opioid intoxication. It is a variant in a series of antibodies (including HY6-F9WT, HY6-F9DHS, and HY6-F9YTE) designed to combat the effects of synthetic opioids. After administration at 40 mg/kg in preclinical models, HY6-F9DF215 demonstrated a half-life of 26.4 days, substantially longer than other variants in the group, indicating potentially favorable pharmacokinetic properties for sustained neutralization of opioids[1][3]. The specific target antigen and detailed mechanism of opioid neutralization are not provided in the available literature, but its mechanism is presumed to involve direct binding and sequestration of synthetic opioid molecules in the bloodstream.